Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label study of continuous subcutaneous ABBV-951 in Parkinson's disease
NL-OMON55829Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of foscarbidopa, sponsored by AbbVie Inc. Started Dec 2019; status: completed.
02
Drugs
foscarbidopa
Beyond the preview
Go deeper on NL-OMON55829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55829.